| Diagnostic age |
39-year-old |
58-year-old |
|
|
MGMT promoter |
Nonmethylated |
Nonmethylated |
|
|
IDH1 gene |
Wild-type |
Wild-type |
|
| ROS1 protein/gene |
No expression |
No expression |
| |
No gain or polysomy |
No gain or polysomy |
|
| ALK protein/gene |
Weak expression 25% |
No expression |
| |
Polysomy chromosome 2.53% and gain in 13% |
No polysomy no gain no amplification |
|
| MET |
Weak + moderate expression 70 and 20%, respectively |
Moderate + strong expression 20 and 80%, respectively |
| |
Polysomy of chromosome 7 and low amplification 36% |
High amplification with clusters in 70% |
|
| Crizotinib sensibility |
Strong benefit with stability |
No benefit |
| |
Treatment at full dose: 2 months; break: 4 months, reduced dose: 12 months |
Treatment during 4 months |
